|
HCV Cirrhosis
Research Funding
(Only
1 study) |
| Grant |
Project Number |
Name |
Cost |
Project Title |
|
NIDDK |
5K24DK002727-09 |
GLENN,
JEFFREY |
$156,104
|
Cirrhosis
and its complications |
|
Liver
Transplant HCV Research Funding |
| |
FundingIC |
Project Number |
Name |
Cost |
Project Title |
| |
NCRR |
5M01RR000051-47 |
STRATHDEE,
STEFFANIE |
$435
|
PHASE II
TRIAL ASSESS SFTY OF IMNOSPRSN W/DRAWAL IN LIVER TRNSPLNT
RECIP W/HEP C |
| |
|
5M01RR000051-47 |
EXLEY,
MARK |
$949
|
A2ALL
LADR PROTOCOL:PRE-TRNSPLNT TRTMNT TO PRVNT RCURRNCE OF HEPC
AFT LVR TRNSPL |
| |
NIDDK |
5R01DK065982-05 |
MOHANAKUMAR, THALACHALLOUR |
$334,102
|
Immune
Response to Hepatitis C in Liver Transplantation |
| |
NINR |
1P01NR010948-01 |
BAILEY,
DONALD |
$78,819
|
Uncertainty management in patients awaiting liver transplant
|
| |
|
|
Total |
|
|
|
HCV Hepatocellular
Carcinoma (HCC) Research Funding |
| Grant
|
Project Number |
Name |
Cost |
Project Title |
|
NCI |
5P01CA123328-02 |
LAU,
DARYL |
$272,798
|
Role of
Inflammation and DNA Damage-Repair in HCV Carcinogenesis |
| |
1R01CA126807-01A1 |
SNYDER,
NED |
$274,523
|
HCV
genetic variation and hepatocellular carcinoma |
| |
1R01CA127481-01A2 |
DAVID,
MICHAEL |
$293,416
|
Hepatocarcinogenesis Secondary to Hepatitis C |
| |
1R21CA133266-01A1 |
SU,
LISHAN |
$200,550
|
Development of 3D Differentiated Hepatocyte Culture Systems
for the Study of HCC |
| |
1Z01BC010893-01 |
VLAHAKIS,
STACEY |
$270,744
|
Tumor
models for the study of inflammation and oncogenesis |
| |
1Z01CP005782-14 |
O'BRIEN,
CHARLES |
$1,060,598 |
Epidemiology of Oncogenic Viruses |
| |
1K22CA128866-01A1 |
BUCK,
MARTINA |
$148,770
|
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR
MECHANISMS |
| |
5K01CA107092-05 |
LINDSAY,
KAREN |
$162,378
|
Hepatocellular carcinoma: targeting HCV replication |
| |
5R21CA128391-02 |
BROWN,
KAREN |
$187,000
|
Randomized trial of doxorubicin beads for arterial
embolization of hepatocellular |
| |
5R01CA122499-02 |
JACOBSON,
KENNETH |
$266,000
|
Oxidative
Stress and Hepatocellular Carcinoma |
| |
5R01CA123544-02 |
TARAKHOVSKY, ALEXANDER |
$237,762
|
Biomarker
for Hepatocellular Carcinoma |
| |
5R01CA125487-02 |
EMERSON,
SUZANNE |
$291,650
|
Surveillance for Hepatocellular Carcinoma among HCV-infected
Veterans |
| |
5R21CA122523-02 |
JERNIGAN,
TERRY |
$150,000
|
Role of
metallothioneins in hepatocellular carcinoma |
| |
2R42CA121506-02 |
MEHTA,
ANAND |
$564,986
|
HCC
diagnostics defined by fucosylated serum biomarkers |
|
NIDDK |
1Z01DK054504-12 |
LINAS,
BENJAMIN |
$503,301
|
Animal
And Culture Models of Viral Hepatitis And Hepatocellular
Carcinoma |
| |
5R01DK066840-05 |
BERETTA,
LAURA |
$345,537
|
Novel
markers for HCV-related HCC |
| |
5R01DK069859-03 |
FORRESTER, JANET |
$482,550
|
Genes
Related to HCC Progression in LD and DD Transplant |
| |
|
Total |
|
|
Source: National Institutes of Health Research Portfolio
Online Reporting Tool (RePORT) Reports,
Data and Analyses of NIH Research Activities
Retrieved on March 18, 2009
http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2008&DCat=Hepatitis+-+C
Permission is granted to use all information from this website
in pursuit of ending NIH's "Trans-Plan" discriminatory practices against HCV
research funding allocations.
Please Credit: HCVets.com Educational Website &
Support Forums for Military Related HCV Exposures.
Contact HepCop
Email:
Staff
|
